Project Grant R01DK140257
- The University of Notre Dame was awarded a $430,375 Project Grant from the National Institute of Biomedical Imaging and Bioengineering (CFDA 93.286) to develop innovative, long-lasting depots for delivering glucagon-like peptide 1 receptor agonists (GLP1-RAs) to treat diabetes and obesity. The project aims to engineer GLP1-RA therapies that can provide multi-month duration of therapeutic function through the use of self-assembling nanofibrillar systems. This research seeks to create GLP1-RA...
- This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $509,265.00 to Cornell University to develop a cell-retaining, subcutaneous device that allows blood vessel penetration and establishment of an immunotolerant environment for islet delivery for type 1 diabetes cell replacement therapy. The goal is to create a cell delivery...
- This $804,342 Project Grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research at Duke University to investigate the metabolic actions of glucagon, a hormone that plays a key role in glucose regulation. Specifically, the research aims to characterize how glucagon receptor signaling in the liver engages divergent pathways that...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), through the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $1,093,967 Project Grant to Persista Bio Inc. in Ithaca, NY. The grant supports the advanced preclinical development of the O2Line system, an oxygenated cell encapsulation device for type 1 diabetes cell replacement therapy. The goal is to develop a safe, anti-fibrotic, and high-capacity cell delivery system that...
- This federal Project Grant award of $803,748 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant is funding research to investigate the modulation of insulin signaling in adipocytes (fat cells) and how improved adipocyte insulin sensitivity can contribute to positive metabolic outcomes. The research team at The University of Texas Southwestern Medical...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $132,270 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Florida. The grant aims to develop a multi-functional 3D-printed biomaterial scaffold that improves the vascularization, engraftment, and immunoprotection of transplanted pancreatic islets for the treatment of type 1 diabetes. The project has two key objectives: 1) Identify...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $235,403 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The Johns Hopkins University. The funding will support the development of a membrane-reconstituted ZNT8 biosensor to detect cell-surface ZNT8 autoantibodies in the peripheral blood of patients with type-1 diabetes. This novel bioanalytical tool aims to enable the early detection of islet...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,778,953 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Regents of the University of Minnesota. The award, with a start date of September 16, 2025 and a completion date of June 30, 2029, will support research on the dynamics of the HIV reservoir and its association with metabolic complications of HIV infection in individuals receiving...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $165,541 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Scripps Health, a nonprofit health system based in San Diego, California. The grant funding will be used to integrate continuous glucose monitoring (CGM) education into the Project DULCE diabetes self-management program to improve glycemic control in Latino adults with type 2 diabetes. Key...
- This federal Project Grant award, in the amount of $531,999.00, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award is supporting research focused on understanding the role of alternative splicing in the proximal tubules of the kidney and its relationship to the progression of diabetic kidney disease. The research will investigate how diabetes...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $745,249 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Notre Dame DU Lac. The project aims to develop a once-weekly and glucose-responsive insulin formulation. The research focuses on chemically modifying insulin with a novel glucose binder and a dendrimer carrier to create a subcutaneous nanocomplex insulin depot that can respond to glucose levels and sustain function for at least a week. Early results in a diabetic swine model demonstrate the depot's ability to promptly increase serum insulin levels in response to glucose challenge. This grant supports further research to address challenges in translating this technology to clinical use, with an award period from September 1, 2025 to June 30, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $745.2k | 9/1/25 |